RLYB Rallybio Corp
Price Chart
Executive Summary
Rallybio Corp (RLYB) entered into a definitive merger agreement to be acquired by Avenzo Therapeutics in a reverse-merger transaction. Rallybio will issue shares to Avenzo stockholders, change its name to Avenzo Therapeutics, Inc., and wind down its existing operations. Concurrently, Avenzo raised $215M in a PIPE financing at closing. The deal represents a change of control and a strategic pivot for Rallybio, effectively becoming a clinical-stage oncology company.
Key Financial Metrics
Actionable Insight
The reverse merger transforms RLYB from a pre-revenue biotech with a single pipeline asset into a well-capitalized clinical-stage oncology company with a $215M cash infusion. The deal provides a clear path forward with a new pipeline and management. Monitor stockholder votes and the SEC registration process for the proxy statement. The CVR structure for existing Rallybio assets creates a potential upside catalyst if those assets are sold.
Key Facts
- Rallybio (RLYB) to merge with Avenzo Therapeutics in a reverse merger; Avenzo stockholders will receive shares of Rallybio common stock.
- Concurrent PIPE financing of $215M at a $300M company valuation for Avenzo.
- Post-merger, the combined company will be named Avenzo Therapeutics, Inc. and focus on Avenzo's pipeline.
- Rallybio will wind down its existing preclinical, CMC, and clinical activities.
- Existing Rallybio stockholders will receive CVRs tied to potential asset sales.
- The deal requires approval from both Rallybio and Avenzo stockholders; closing expected by November 30, 2026.
- Rallybio's board has unanimously approved the transaction and recommends it to stockholders.
Financial Impact
Avenzo valued at $300M in the merger; concurrent PIPE of $215M provides substantial capital for the combined entity.
Risk Factors
- Stockholder approval risk for both companies; failure to obtain required votes could terminate the deal.
- Execution risk in winding down Rallybio's existing operations and integrating Avenzo's team and pipeline.
- Dilution for existing Rallybio stockholders; the exchange ratio implies a significant change in ownership.
- Regulatory and Nasdaq listing approval risks.
- Avenzo's pipeline is still in clinical/preclinical stages; no guarantee of eventual regulatory approval.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249790 |
| Document: d19106dex105.htm | 0001193125-26-249790 |
| Document: d19106dex106.htm | 0001193125-26-249790 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
13d ago
|
425
| $16.87 $15.95 | ▼ −5.45% | ▼ −2.70% | $15.92 (−5.63%) |
|
Jun 1, 2026
13d ago
|
8-K
| $16.87 $15.95 | ▼ −5.45% | ▼ −2.70% | $15.92 (−5.63%) |
|
May 4, 2026
5w ago
|
8-K
| $14.12 $14.00 | ▼ −0.85% | ▼ −3.79% | $15.92 (+12.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access